Medizone International Completes Arrangements to Manufacture Equipment for Use in Collaborative Clinical Trials in Italy to Study Effect of Ozone Therapy on AIDS, Hepatitis B Patients. September 8, 1993, New York, New York...........Medizone International, Inc. (OTC-MZEI) announced today the completion of contractual arrangements for the manufacture of he hardware components of five Medizone Drug Delivery Systems. This equipment is intended to be delivered to Italy for use in a collaborative research project designed to examine, in Phase 1 clinical trials, the efficacy of ozone therapy and Medizone's patented technology in the treatment of various blood-related human diseases, including AIDS and Hepatitis B. Medizone President Dr. Joseph S. Latino explained that the manufacture of the hardware components of the five Medizone Drug Delivery Systems for shipment to Italy is a major step towards fulfillment of the Company's obligations under the collaborative arrangement. The hardware, at an approximate cost of $68,500, will incorporate, at an additional cost, disposable gas exchange modules, devices within the scope of the Company's proprietary thin film technology process. By letter agreement with the Italian Scientific Society for Oxygen-Ozone Therapy ("ISSOT") executed in March, 1993, the Company also agreed to provide FDA approved protocols for use by the research group, which was designated by the Italian Ministry of Health to sponsor the project. Dr. Latino has been invited to join the research group. Further communications with the ISSOT indicate that an estimated 300 patients are expected to participate in the trials, to be conducted at five university-based Italian hospitals over a period of approximately nine months. In accordance with the treatment protocol, patients will undergo a one-hour treatment procedure on alternate days during the course of a twelve-week period. The treatment consists of the withdrawal of 300 cc. (approximately ten ounces) of blood, to be interfaced with ozone/oxygen gas through extracorporeal circulation (outside the body), and then reinfused into the patient. Patients will continue to be clinically monitored for at least nine months after completion of treatment. Dr. Latino reiterated the Company's recent announcement of the successful completion of two stages of a Canadian research project that demonstrated preliminary scientific evidence supporting the use of Medizone's proprietary blood decontamination technology in a live primate (monkey) model, further evidencing the scientific rational toward achieving human trial status. Medizone International Inc. is developing, Medizone(TM), an ozone-based treatment for diseases caused by lipid enveloped viruses, including Acquired Immunodeficiency Syndrome (AIDS), hepatitis B, and herpes; and is also developing its patented technology for the decontamination of blood and blood products.